{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:31:37Z","timestamp":1794335497947,"version":"4.9.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s13300-026-01843-x","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T06:48:34Z","timestamp":1771224514000},"page":"449-459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluating the Effects of Glucagon-Like Peptide 1 Receptor Agonists as a Secondary Prevention in Peripheral Arterial Disease: A Meta-Analysis"],"prefix":"10.1007","volume":"17","author":[{"given":"Beth","family":"Elliott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirali","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Heald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin C.","family":"Field","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Heiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2897-2026","authenticated-orcid":false,"given":"Martin B.","family":"Whyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"10193","key":"1843_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et\u00a0al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"Lancet"},{"issue":"10157","key":"1843_CR2","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, D\u2019Agostino RB Sr., Granger CB, Jones NP, et\u00a0al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(18)32261-X.","journal-title":"Lancet"},{"issue":"19","key":"1843_CR3","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et\u00a0al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"4","key":"1843_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et\u00a0al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"6","key":"1843_CR5","doi-asserted-by":"publisher","first-page":"827","DOI":"10.4239\/wjd.v12.i6.827","volume":"12","author":"DO Soyoye","year":"2021","unstructured":"Soyoye DO, Abiodun OO, Ikem RT, Kolawole BA, Akintomide AO. Diabetes and peripheral artery disease: a review. World J Diabetes. 2021;12(6):827\u201338. https:\/\/doi.org\/10.4239\/wjd.v12.i6.827.","journal-title":"World J Diabetes"},{"issue":"10","key":"1843_CR6","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.2337\/dc18-1094","volume":"41","author":"K Dhatariya","year":"2018","unstructured":"Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, et\u00a0al. The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER trial. Diabetes Care. 2018;41(10):2229\u201335. https:\/\/doi.org\/10.2337\/dc18-1094.","journal-title":"Diabetes Care"},{"issue":"1","key":"1843_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","volume":"40","author":"J Helmstadter","year":"2020","unstructured":"Helmstadter J, Frenis K, Filippou K, Grill A, Dib M, Kalinovic S, et\u00a0al. Endothelial GLP-1 (glucagon-like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension. Arterioscler Thromb Vasc Biol. 2020;40(1):145\u201358. https:\/\/doi.org\/10.1161\/atv.0000615456.97862.30.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"1843_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06712-z","volume":"7","author":"Q Li","year":"2017","unstructured":"Li Q, Lin Y, Wang S, Zhang L, Guo L. GLP-1 inhibits high-glucose-induced oxidative injury of vascular endothelial cells. Sci Rep. 2017;7(1):8008. https:\/\/doi.org\/10.1038\/s41598-017-06712-z.","journal-title":"Sci Rep"},{"issue":"6","key":"1843_CR9","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1161\/ATVBAHA.124.320714","volume":"44","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Wang S, Zhou Q, Xie Y, Hu Y, Fang W, et\u00a0al. Novel angiogenesis role of GLP-1(32-36) to rescue diabetic ischemic lower limbs via GLP-1R-dependent glycolysis in mice. Arterioscler Thromb Vasc Biol. 2024;44(6):1225\u201345. https:\/\/doi.org\/10.1161\/ATVBAHA.124.320714.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"1843_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et\u00a0al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1\u201312. https:\/\/doi.org\/10.1016\/0197-2456(95)00134-4.","journal-title":"Control Clin Trials"},{"key":"1843_CR11","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et\u00a0al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"1","key":"1843_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-015-0024-z","volume":"15","author":"PT von Hippel","year":"2015","unstructured":"von Hippel PT. The heterogeneity statistic I(2) can be biased in small meta-analyses. BMC Med Res Methodol. 2015;15(1):35. https:\/\/doi.org\/10.1186\/s12874-015-0024-z.","journal-title":"BMC Med Res Methodol"},{"issue":"12","key":"1843_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.119.008018","volume":"12","author":"A Badjatiya","year":"2019","unstructured":"Badjatiya A, Merrill P, Buse JB, Goodman SG, Katona B, Iqbal N, et\u00a0al. Clinical outcomes in patients with type 2 diabetes mellitus and peripheral artery disease: results from the EXSCEL trial. Circ Cardiovasc Interv. 2019;12(12):e008018. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.119.008018.","journal-title":"Circ Cardiovasc Interv"},{"issue":"10489","key":"1843_CR14","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","volume":"405","author":"MP Bonaca","year":"2025","unstructured":"Bonaca MP, Catarig AM, Houlind K, Ludvik B, Nordanstig J, Ramesh CK, et\u00a0al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025;405(10489):1580\u201393. https:\/\/doi.org\/10.1016\/S0140-6736(25)00509-4.","journal-title":"Lancet"},{"issue":"10","key":"1843_CR15","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00125-004-1525-1","volume":"47","author":"S Srinivasan","year":"2004","unstructured":"Srinivasan S, Hatley ME, Bolick DT, Palmer LA, Edelstein D, Brownlee M, et\u00a0al. Hyperglycaemia-induced superoxide production decreases enOS expression via AP-1 activation in aortic endothelial cells. Diabetologia. 2004;47(10):1727\u201334. https:\/\/doi.org\/10.1007\/s00125-004-1525-1.","journal-title":"Diabetologia"},{"key":"1843_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063346","author":"S Jebari-Benslaiman","year":"2022","unstructured":"Jebari-Benslaiman S, Galicia-Garcia U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K, et\u00a0al. Pathophysiology of atherosclerosis. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23063346.","journal-title":"Int J Mol Sci"},{"key":"1843_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010026","author":"YS Oh","year":"2017","unstructured":"Oh YS, Jun HS. Effects of glucagon-like peptide-1 on oxidative stress and Nrf2 signaling. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms19010026.","journal-title":"Int J Mol Sci"},{"key":"1843_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109076","volume":"180","author":"FC Hsiao","year":"2021","unstructured":"Hsiao FC, Lin CP, Tung YC, Wu CT, Chu PH. Major adverse limb events in type 2 diabetes patients receiving glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a retrospective multi-institutional study. Diabetes Res Clin Pract. 2021;180:109076. https:\/\/doi.org\/10.1016\/j.diabres.2021.109076.","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"1843_CR19","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1007\/s00125-022-05772-9","volume":"65","author":"DS Lin","year":"2022","unstructured":"Lin DS, Yu AL, Lo HY, Lien CW, Lee JK, Chen WJ. Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors. Diabetologia. 2022;65(12):2032\u201343. https:\/\/doi.org\/10.1007\/s00125-022-05772-9.","journal-title":"Diabetologia"},{"issue":"21","key":"1843_CR20","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMc1712572","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(21):2099. https:\/\/doi.org\/10.1056\/NEJMc1712572.","journal-title":"N Engl J Med"},{"issue":"14","key":"1843_CR21","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1161\/CIRCULATIONAHA.117.031227","volume":"137","author":"JA Udell","year":"2018","unstructured":"Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N. Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world). Circulation. 2018;137(14):1450\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.031227.","journal-title":"Circulation"},{"key":"1843_CR22","doi-asserted-by":"publisher","first-page":"k4365","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda P, Svanstrom H, Melbye M, Eliasson B, Svensson AM, Franzen S, et\u00a0al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365. https:\/\/doi.org\/10.1136\/bmj.k4365.","journal-title":"BMJ"},{"issue":"1","key":"1843_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86516-4","volume":"11","author":"HY Chang","year":"2021","unstructured":"Chang HY, Chou YY, Tang W, Chang GM, Hsieh CF, Singh S, et\u00a0al. Association of antidiabetic therapies with lower extremity amputation, mortality and healthcare cost from a nationwide retrospective cohort study in Taiwan. Sci Rep. 2021;11(1):7000. https:\/\/doi.org\/10.1038\/s41598-021-86516-4.","journal-title":"Sci Rep"},{"issue":"10","key":"1843_CR24","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.2337\/dc20-0267","volume":"43","author":"OHY Yu","year":"2020","unstructured":"Yu OHY, Dell\u2019Aniello S, Shah BR, Brunetti VC, Daigle JM, Fralick M, et\u00a0al. Sodium-glucose cotransporter 2 inhibitors and the risk of below-knee amputation: a multicenter observational study. Diabetes Care. 2020;43(10):2444\u201352. https:\/\/doi.org\/10.2337\/dc20-0267.","journal-title":"Diabetes Care"},{"issue":"10","key":"1843_CR25","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1111\/dom.14091","volume":"22","author":"C Arnott","year":"2020","unstructured":"Arnott C, Huang Y, Neuen BL, Di Tanna GL, Cannon CP, Oh R, et\u00a0al. The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial. Diabetes Obes Metab. 2020;22(10):1753\u201366. https:\/\/doi.org\/10.1111\/dom.14091.","journal-title":"Diabetes Obes Metab"},{"key":"1843_CR26","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-0292","author":"AT Hong","year":"2025","unstructured":"Hong AT, Luu IY, Lin F, Shin L, Hsu CH, Shih CD, et\u00a0al. Differential effect of GLP-1 receptor agonists and SGLT2 inhibitors on lower-extremity amputation outcomes in type 2 diabetes: a nationwide retrospective cohort study. Diabetes Care. 2025. https:\/\/doi.org\/10.2337\/dc25-0292.","journal-title":"Diabetes Care"},{"issue":"4","key":"1843_CR27","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/ehjqcco\/qcad011","volume":"9","author":"MM Kavurma","year":"2023","unstructured":"Kavurma MM, Boccanfuso L, Cutmore C, Passam F, Patel S, Hennessy A, et\u00a0al. A hidden problem: peripheral artery disease in women. Eur Heart J Qual Care Clin Outcomes. 2023;9(4):342\u201350. https:\/\/doi.org\/10.1093\/ehjqcco\/qcad011.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"1843_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014State-of-the-art. Mol Metab. 2021;46:101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102.","journal-title":"Mol Metab"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01843-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01843-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01843-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:21:54Z","timestamp":1773822114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01843-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1843"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01843-x","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Beth Elliot, Ellie Tomlinson, Nirali Desai, Adrian Heald, Ben Field, Christian Heiss, and Martin Whyte have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. No ethical approval was required as the study was a meta-analysis of existing, published data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}